Stockscreener 앱 받기
8.70
1.16%
0.10
전일 마감가:
$8.60
열려 있는:
$8.68
하루 거래량:
306.84K
Relative Volume:
0.99
시가총액:
$415.53M
수익:
$36.90M
순이익/손실:
$-166.28M
주가수익비율:
-2.6444
EPS:
-3.29
순현금흐름:
$-203.53M
1주 성능:
+1.64%
1개월 성능:
+22.54%
6개월 성능:
-32.97%
1년 성능:
-64.40%
1일 변동 폭
$8.51
$8.91
1주일 범위
$8.205
$9.0702
52주 변동 폭
$6.10
$28.67
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
명칭
Bicycle Therapeutics Plc Adr
전화
011441223261503
주소
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
BCYC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
8.70 | 595.58M | 36.90M | -166.28M | -203.53M | -3.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-08 | 개시 | Stephens | Equal-Weight |
| 2024-09-06 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-07 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-09-11 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2022-08-31 | 개시 | Cowen | Outperform |
| 2022-07-28 | 개시 | Barclays | Overweight |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-04-13 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2022-04-07 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-02-14 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | SVB Leerink | Outperform |
| 2021-12-09 | 개시 | Needham | Buy |
| 2021-09-30 | 개시 | B. Riley Securities | Buy |
| 2021-04-20 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-06-12 | 개시 | Oppenheimer | Outperform |
| 2020-04-17 | 개시 | H.C. Wainwright | Buy |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-09-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-06-17 | 개시 | Canaccord Genuity | Buy |
| 2019-06-17 | 개시 | Goldman | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
| 2019-06-17 | 개시 | Piper Jaffray | Overweight |
모두보기
Bicycle Therapeutics Plc Adr 주식(BCYC)의 최신 뉴스
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Teacher Retirement System of Texas - Defense World
Principal Financial Group Inc. Boosts Stock Position in Schneider National, Inc. (NYSE:SNDR) - Defense World
Principal Financial Group Inc. Purchases 1,695 Shares of Monarch Casino & Resort, Inc. (NASDAQ:MCRI) - Defense World
Teacher Retirement System of Texas Has $465,000 Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Teacher Retirement System of Texas Sells 1,266 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
William Blair Brokers Decrease Earnings Estimates for TLX - Defense World
Principal Financial Group Inc. Purchases 5,315 Shares of Aaron’s Holdings Company, Inc. (NYSE:PRG) - Defense World
First Northwest Bancorp (FNWB) Expected to Announce Quarterly Earnings on Thursday - Defense World
Principal Financial Group Inc. Acquires 17,237 Shares of Upbound Group, Inc. (NASDAQ:UPBD) - Defense World
The Bank of Nova Scotia (TSE:BNS) Receives Average Rating of “Hold” from Analysts - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up – Should You Buy? - Defense World
Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com India
Market Update: Bicycle Therapeutics Plc ADR (BCYC) Sees Negative Movement, Closing at 7.40 - DWinneX
Bicycle Therapeutics earnings missed by $0.03, revenue topped estimates - Investing.com South Africa
How should investors view Bicycle Therapeutics Plc ADR (BCYC)? - uspostnews.com
PBF Energy Inc [PBF] Records 50-Day SMA of $19.79 - knoxdaily.com
UGI Corp [UGI] Records 200-Day SMA of $27.63 - knoxdaily.com
Cellebrite DI Ltd [NASDAQ: CLBT] Sees Increase in Stock Value - knoxdaily.com
Bicycle Therapeutics Plc ADR [BCYC] Shares Fall -0.69 % on Wednesday - knoxdaily.com
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading - MSN
Bicycle Therapeutics Plc ADR Inc. (BCYC) Price Performance: The Role of Supply and Demand - investchronicle.com
Fastenal Co (FAST) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock By Investing.com - Investing.com India
Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 By Investing.com - Investing.com South Africa
Bicycle therapeutics COO Alistair Milnes sells $16,850 in stock By Investing.com - Investing.com South Africa
Bicycle Therapeutics chief product officer sells shares worth $5,735 - Investing.com
Bicycle Therapeutics CEO Lee Kevin sells shares worth $43,612 - Investing.com
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 - Investing.com
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock - Investing.com
Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 - Investing.com
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 By Investing.com - Investing.com UK
Bicycle Therapeutics stock hits 52-week low at $8.6 amid downturn By Investing.com - Investing.com South Africa
Bicycle Therapeutics reshuffles leadership, aims for oncology advances By Investing.com - Investing.com South Africa
Bicycle Therapeutics reshuffles leadership, aims for oncology advances - Investing.com India
Bicycle Therapeutics stock hits 52-week low at $8.98 By Investing.com - Investing.com South Africa
Bicycle Therapeutics’ SWOT analysis: innovative platform drives stock potential - Investing.com India
Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Jefferies cuts Bicycle Therapeutics price target to $42 from $53 By Investing.com - Investing.com South Africa
Bicycle Therapeutics stock holds $33 target, Buy rating at Rodman By Investing.com - Investing.com South Africa
Mizuho maintains Harmony Biosciences $42 target, Outperform rating - Investing.com India
Mizuho maintains Harmony Biosciences $42 target, Outperform rating By Investing.com - Investing.com South Africa
Bicycle Therapeutics' SWOT analysis: platform potential drives stock outlook - Investing.com
Bicycle Therapeutics reports promising cancer drug trial results - Investing.com
Bicycle Therapeutics exec sells $30k in shares - Investing.com
Bicycle Therapeutics spotlights cancer treatment targets - Investing.com
Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - Yahoo Finance
Oppenheimer backs Bicycle Therapeutics' BRC platform, reiterates $48 stock PT - Investing.com UK
Bicycle therapeutics CEO sells shares worth over $71k - Investing.com
South Korea Peptide Drug Conjugates Market Size & Outlook, 2030 - Grand View Research
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio - Yahoo Finance
Bicycle Therapeutics Plc Adr (BCYC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.22%
자본화:
|
볼륨(24시간):